O-RAN-ALLIANCE
In December 2020, the O-RAN Software Community (OSC), working with the Linux Foundation, published its 3rd open software release within 18 months, dubbed “Cherry”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005829/en/
Cherry moves the O-RAN ecosystem closer to commercial deployments in mobile networks around the globe. On top of new functions aligned with the latest O-RAN specifications, such as the E2, A1 and O1 interfaces, this release also features significant advancements in the end-to-end integration of O-RAN Architecture components to meet the needs of early adopters. In addition, new software projects in the area of Service Management and Orchestration (SMO) have been initiated to drive the development of auto-configuration and management of O-RAN elements.
The main use cases delivered in Cherry include:
- Policy based Traffic Steering using the A1 and E2 interfaces
- Automated Monitoring and Health check of selected components using the O1 interface
- Configuration, Fault and Performance Management Services aligned with OAM models and specifications newly approved by O-RAN
- Life Cycle Management Framework of rApps and xApps using SMO
- O-DU Low and High pairwise testing in O-RAN Software Community lab
- Simulators for testing and integration, such as E2, A1, Open Test Framework, and more
“It is gratifying to see the continued momentum of the OSC’s open-source O-RAN implementation,” said Jack Murray, co-chair of the OSC Technical Operating Committee (TOC) and Assistant Vice President of AT&T. “AT&T is proud to have continued its contributions to enable RAN AI/ML through the Near-Real Time RIC implementation, and to provide a platform for software testing and integration.”
“We are glad to see Cherry has made big progress by building on the base of Bronze,” said Chih-Lin I, the Co-Chair of O-RAN Technical Steering Committee. “It not only realizes more 3GPP-defined models, but also brings O-RAN defined interfaces including E2 and A1 closer to commercialization. More ML and AI technologies are implemented in the RIC, RICAPP and NRTRIC projects to push the traffic steering e2e use case forward, which makes it a more intelligent RAN. The newly created SMO project is also worth special mention for the quick momentum that it has gained in contributing to O-RAN automation and management within just 3 months.”
“Nokia continues to be very active in O-RAN and a major contributor to the O-RAN specifications,” said Pasi Toivanen, Head of Edge Cloud Platforms at Nokia. “With the Cherry Release, Nokia is contributing to the Near-Real-Time RIC and the E2 interface to advance RAN programmability, network openness, and the introduction of AI/ML intelligence to the network. The contributions also deliver increased robustness, more xApp framework capabilities and enhanced manageability of RIC platform and xApps.”
“Radisys continues to contribute actively to O-RAN standardization and open source development. In the Cherry release, Radisys enhanced O-DU L2 implementation to support UE attach, and integrated with PHY (O-DU Low) through the FAPI interface to enable end-to-end testing," said Ganesh Shenbagaraman, Head of Integrated Products and Ecosystems at Radisys.
“highstreet technologies substantially contributes to O1/OAM within both O-RAN and OSC,” said Alfons Mittermaier, Managing Director of highstreet technologies. “We expect the disaggregated O-RAN architecture to become a door opener for small and medium sized enterprises and will deploy the Cherry release in a 5G reference network in Berlin.”
“HCL has contributed to the O-RAN Software Community across different Work Groups starting with the Cherry Release,” said Ramesh Sriraman, the Head of Telecom Center of Excellence at HCL. “We Improved Near-Real-Time RIC platform CI/CD deployment, automation, performance & scale; introduced AI/ML intelligence to RAN network via xApps; and contributed the initial implementation of the O-RAN O1 interface in the O-DU. It is a great honor for HCL to develop together with the OSC team.”
To learn more about the O-RAN Software Community Cherry release please read this O-RAN Blog post , and to access the code, check out the O-RAN Software Community website .
The O-RAN Software Community continues to be open to any participants that want to get involved in the creation of software for future RAN – for more details please visit https://www.o-ran.org/software .
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 240 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information please visit www.o-ran.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005829/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom